6/28/23, 12:17 AM CORONA Pathway Feedback Search Clinical Topics Home Studies CORONA CORONA Disease Disease Disease Dilated cardiomyopathy Dyslipidemia Heart f Trial question What is the role of rosuvastatin in older patients with systolic HF (NYHA class II, III or IV) secondary to ischemic cardiomyopathy? Study design Multi-center Double blinded RCT Population Characteristics of study participants 24.0% female N = 5011 76.0% male 5011 patients (1180 female, 3831 male) Inclusion criteria: patients with systolic HF (NYHA class II, III or IV) secondary to ischemic cardiomyopathy Key exclusion criteria: previous statin-induced myopathy or hypersensitivity reaction; decompensated HF or a need for inotropic therapy; myocardial infarction within the past 6 months; unstable angina or stroke within the past 3 months; PCI, CABG, or the implantation of a cardioverter-defibrillator or biventricular pacemaker within the past 3 months Interventions N=2514 rosuvastatin (10 mg PO once daily) N=2497 placebo (matching placebo once daily) Primary outcome Death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke https://web.pathway.md/studies/recUTv9yPgrBZnNhp 1/2 6/28/23, 12:17 AM CORONA Pathway 14.6 % 14.6 13.8 10.9 % 7.3 % 3.6 % No significant difference 0.0 % Rosuvastatin Placebo No significant difference in death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke (13.8% vs. 14.6%; HR 0.92, 95% CI 0.83 to 1.02) Secondary outcomes No significant difference in the incidence of death from any cause (11.6 /100 py vs. 12.2 /100 py; HR 0.95, 95% CI 0.86 to 1.05) No significant difference in coronary event (9.3 vs. 10; HR 0.92, 95% CI 0.82 to 1.04) Safety outcomes No significant difference in muscle-related adverse events or other adverse events. Conclusion In patients with systolic HF (NYHA class II, III or IV) secondary to ischemic cardiomyopathy, rosuvastatin was not superior to placebo with respect to death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke. Reference Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007 Nov 29;357(22):2248-61. Open reference URL https://web.pathway.md/studies/recUTv9yPgrBZnNhp 2/2